The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus
Autor: | Dirk Vordermark, Simone Marnitz, Daniel Medenwald, Victor Izaguirre, Frank Sieker |
---|---|
Rok vydání: | 2020 |
Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.medical_treatment Brachytherapy brachytherapy carcinosarcoma Review lcsh:RC254-282 law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law Internal medicine Carcinosarcoma medicine Stage (cooking) Lymph node radiotherapy Chemotherapy 030219 obstetrics & reproductive medicine uterus business.industry lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Cancer registry Radiation therapy medicine.anatomical_structure 030220 oncology & carcinogenesis business |
Zdroj: | Cancers Cancers, Vol 12, Iss 3573, p 3573 (2020) |
ISSN: | 2072-6694 |
Popis: | Simple Summary The role of radiotherapy on carcinosarcoma, a rare malignant tumor, of the uterus is unclear. We reviewed data published from 2010 on the effects of radiotherapy on tumor control and survival in this patient group. Available data were mainly from cancer registries and suggested that radiotherapy, given either as vaginal brachytherapy (contact radiotherapy of the vagina) or external-beam radiotherapy or a combination of both, reduces the risk of recurrence and improves survival in patients with all stages of carcinosarcoma of the uterus without metastases in other organs. Abstract The role of postoperative radiotherapy delivered as external-beam radiotherapy (EBRT), vaginal brachytherapy (VBT) or a combination of both, in the management of carcinosarcoma of the uterus is not clearly defined, as only limited randomized trial data are available, indicating a reduction in locoregional recurrences after EBRT. We performed a structured review of data published from 2010. Although no relevant new data from prospective trials or meta-analyses were identified, 14 analyses of cancer registry data from the United States or Europe, focusing predominantly on the endpoint for overall survival, were identified, four of them using propensity-score matching to compare subgroups treated with vs. without radiotherapy. Although stage-by-stage data are rare, the registry analyses support the idea of a beneficial effect, especially of VBT, on overall survival in International Federation of Gynecology and Obstetrics (FIGO) stage IA patients (to a lesser extent in stage IB). For stages II to III, the data sets indicate the largest effects on overall survival for the combination of EBRT and VBT. In all stages, survival effects of radiotherapy apparently persist when given in addition to chemotherapy. Whereas some studies see the strongest survival effects in patients with positive lymph nodes, propensity-score matched data indicate an overall survival effect of radiotherapy (EBRT + VBT or VBT alone) in FIGO stages I to III regardless of lymph node surgery. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |